APA (7th ed.) Citation

Alhadrami, H. A., Sayed, A. M., Al-Khatabi, H., Alhakamy, N. A., & Rateb, M. E. (2021). Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M^Pro Inhibitor. MDPI AG.

Chicago Style (17th ed.) Citation

Alhadrami, Hani A., Ahmed M. Sayed, Heba Al-Khatabi, Nabil A. Alhakamy, and Mostafa E. Rateb. Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M^Pro Inhibitor. MDPI AG, 2021.

MLA (8th ed.) Citation

Alhadrami, Hani A., et al. Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M^Pro Inhibitor. MDPI AG, 2021.